

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/724,608	12/02/2003	Hiroyuki Kometani	380-45	3708
23117 7 NIXON & VAN	7590 03/08/200 IDERHYE PC	EXAMINER		
901 NORTH GLEBE ROAD, 11TH FLOOR			SERGENT, RABON A	
ARLINGTON,	VA 22203		ART UNIT	PAPER NUMBER
			1711	
SHORTENED STATUTORY	PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE	
3 MON	NTHS	03/08/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

		h/				
	Application No.	Applicant(s)				
Office Action Cumment	10/724,608	KOMETANI ET AL.				
Office Action Summary	Examiner	Art Unit				
	Rabon Sergent	1711				
The MAILING DATE of this communication app Period for Reply	ears on the cover sneet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filled after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on 15 De	ecember 2006.					
2a) ☐ This action is FINAL . 2b) ☑ This	- Control of the Cont					
3) Since this application is in condition for allowar	☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
 4) Claim(s) 20,21 and 23-26 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) 20,21 and 23-26 is/are rejected. 						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or	r election requirement.					
Application Papers						
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the correction to the correction and the correction of the	epted or b) objected to by the Edrawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119		•				
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 09/973,747. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa 6) Other:	te				

Application/Control Number: 10/724,608

Art Unit: 1711

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on November 20, 2006 has been entered.

- 2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

3. Claims 20, 21, and 23-26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hagio et al. ('104) in view of Laas et al. ('044) and Nakamura et al. ('034) and Hannah et al. ('659).

Hagio et al. disclose the use of salts of cycloamidines, such as applicants' claimed DBU, DBN, and DBD, as catalysts for polyurethane compositions. Patentees further disclose that the aforementioned salts can be produced from the reaction of the aforementioned cycloamidines

Art Unit: 1711

with unsaturated acids, such as crotonic acid, acrylic acid, and ricinoleic acid. See abstract; column 2; and column 3, lines 14-19.

- 4. In addition to the teachings of Hagio et al, Nakamura et al. disclose at column 5, lines 1-40, especially lines 1-4, that salts of DBU were known catalysts for polyurethanes, and Laas et al. disclose at column 4, line 65 through column 5, line 13 that bicyclic amidines corresponding to those of applicants were known catalysts for polyurethane yielding coating compositions. Though the aforementioned references fail to specifically recite the use of the catalysts within two-component isocyanate based systems, the use of salts of DBU and DBN within such systems was known at the time of invention, as evidenced by Hannah et al. at column 4, line 65 through column 5, line 27. Furthermore, since the salt forms in a one to one ratio of catalyst to acid, applicants' claimed ratio limitations are considered to be satisfied.
- Therefore, in view of the aforementioned teachings, the position is taken that it would have been obvious to utilize salts derived from unsaturated acids and cyclic amidines, such as DBU, DBN, and DBD, in their art recognized capacity as catalysts for polyurethane and isocyanate based polymeric systems, and that it further would have been obvious to utilize the salts in virtually any type of polyurethane yielding system, including two-component systems. Lastly, the position is taken that the use of virtually any unsaturated acid to block the catalyst would have been obvious in view of the teachings of the references.
- 6. Applicants' response of November 20, 2006 and the 37 CFR 1.132 declaration of June 7, 2006 have been considered; however, the response and declaration are insufficient to overcome the prior art rejection. The examiner has considered applicants' examples; however, it is not seen that applicants have provided showings commensurate in scope with the claims to rebut the

Art Unit: 1711

prima facie case of obviousness. Despite applicants' arguments, applicants' claims and examples are not commensurate in scope in terms of catalyst species, acid species, quantities of reactants, quantities of catalyst, and ratios of catalyst to acid. It has been held that evidence of unexpected results, must pertain to the full extent of the subject matter being claimed. In re Ackermann, 170 USPQ 340; In re Chupp, 2 USPQ2d 1437; In re Murch, 175 USPQ 89. Accordingly, to overcome a prima facie case of obviousness, the claims must be commensurate in scope with any showing of unexpected results. In re Greenfield, 197 USPQ 227. Furthermore, it has been held that a limited showing of criticality is insufficient to support a broadly claimed range. In re Lemin, 161 USPQ 288; In re Kulling, 14 USPQ2d 1056. Furthermore, to the extent that the examples and claims are commensurate in scope, it remains unclear that applicants' results are in fact unexpected. In the instant case, the position is maintained that the evidence of obviousness outweighs the evidence of non-obviousness. One of ordinary skill in the art, in the course of routine experimentation, would have been able to select suitable acid blocked catalysts yielding optimum results, in terms of such properties as pot-life and viscosity increase. This issue has been set forth previously, however, applicants have not addressed the issue.

Any inquiry concerning this communication should be directed to R. Sergent at telephone number (571) 272-1079.

RABON SERGENT PRIMARY EXAMINER

R. Sergent March 5, 2007